β-Funaltrexamine
Based on 2 publication(s) in Google Scholar
β-Funaltrexamine (β-FNA) is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases.
For research use only. We do not sell to patients.
- CAS No.: 72782-05-9
- Formula: C25H30N2O6
- Molecular Weight:454.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) β-Funaltrexamine
MoreAll Opioid Receptor Isoforms
More
Biological Activity
Description
|
μ Opioid Receptor/MOR |
iNOS |
NF-κB |
TLR4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | Inhibition |
0.49 %
Compound: BETA-FUNALTREXAMINE
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
10.21203/rs.3.rs-23951/v1 |
In Vitro
β-Funaltrexamine (0.3-100 μM; 24 h) concentration-dependently inhibits IL-1β-induced CXCL10 protein expression in normal human astrocytes with an EC50 of 7.6 μM, with greater inhibitory efficacy when combined with the ubiquitin-activating enzyme E1 inhibitor PYR41[2].
β-Funaltrexamine (10 μM; 8 h) significantly inhibits IL-1β-induced CXCL10 mRNA expression in normal human astrocytes after 8 h of co-incubation[2].
β-Funaltrexamine (10 μM; 60 min pre-treatment/remainder of 24 h total incubation) produces persistent, washout-resistant inhibition of IL-1β-induced CXCL10 expression in normal human astrocytes, and can inhibit CXCL10 expression when added 6 h after initial IL-1β stimulation[2].
β-Funaltrexamine (10 μM; 10, 30 min) significantly inhibits IL-1β-induced p38 MAPK activation in normal human astrocytes at 10 and 30 min of co-incubation[2].
β-Funaltrexamine (10 μM; 90, 270 min) significantly inhibits IL-1β-induced A20 protein expression in normal human astrocytes at 90 and 270 min of co-incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
β-Funaltrexamine (28 mg/kg; i.p.; single injection) significantly inhibits LPS-induced brain CXCL10 expression in male C57BL/6J mice, demonstrating anti-inflammatory activity in a neuroinflammation model[2].
β-FNA (12.5-50 mg/kg; i.p.; single dose) significantly inhibits LPS-induced CXCL10 and CCL2 expression in the brain of male C57BL/6J mice, and the 50 mg/kg dose prevents LPS-induced reductions in locomotor activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 72782-05-9
-
Molecular Weight 454.52
-
Formula C25H30N2O6
-
SMILES
O[C@]12[C@@]34C5=C(C[C@@]2([H])N(CC4)CC6CC6)C=CC(O)=C5O[C@@]3([H])[C@@H](CC1)NC(/C=C/C(OC)=O)=O
-
Synonyms
β-FNA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
2026 Feb 13;12(7):eaea9832. PMID: 41671375 -
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Purity & Documentation
References
[1]. Wu CC, et al. β-Funaltrexamine Displayed Anti-inflammatory and Neuroprotective Effects in Cells and Rat Model of Stroke. Int J Mol Sci. 2020;21(11):3866. Published 2020 May 29. [Content Brief]
[2]. Davis RL, et al. The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice. Eur J Pharmacol. 2015;762:193-201. [Content Brief]
[3]. Davis RL, et al. The opioid antagonist, β-funaltrexamine, inhibits lipopolysaccharide-induced neuroinflammation and reduces sickness behavior in mice. Physiol Behav. 2017;173:52-60. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)